Health Economics›Prostate cancer›Hormonal therapy for metastatic or locally advanced disease

Hormonal therapy for metastatic or locally advanced disease

Prostate cancer · 26 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
ADT, Darolutamide, Docetaxel Variant #01	—	R 24 946	21d	—	—	—	—	1
Docetaxel, Estramustine, Goserelin Variant #01 Partial	—	R 17 698	90d	—	—	—	—	—
ADT, Enzalutamide, Talazoparib Variant #01 Partial	—	R 14 528	28d	—	—	—	—	2
Goserelin monotherapy Variant #04	—	R 10 511	84d	—	—	—	—	—
Bicalutamide and Goserelin Variant #01	—	R 8 166	84d	—	—	—	—	1
Degarelix monotherapy Variant #01	—	R 7 595	84d	—	—	—	—	—
Flutamide and Leuprolide Variant #01	—	R 6 666	28d	—	69.6 mo	—	—	1
Flutamide and Goserelin Variant #01	—	R 3 653	28d	—	69.6 mo	—	—	1
Leuprolide monotherapy Variant #01	—	R 2 266	90d	—	—	—	—	2
ADT and Docetaxel Variant #01	—	R 2 069	21d	—	58.3 mo	—	—	4
Bicalutamide and Leuprolide Variant #01	—	R 1 976	28d	24.7 mo	70.2 mo	27	R 53 360 PFS proxy	3
Bicalutamide monotherapy Variant #01	—	R 1 396	28d	—	—	—	—	1
ADT and Apalutamide Variant #01	—	R 1 206	—	—	73.9 mo	—	—	2
Flutamide monotherapy Variant #01	—	R 1 025	28d	—	—	—	—	—
Triptorelin monotherapy Variant #01	—	R 973	28d	—	—	—	—	—
ADT and Enzalutamide Variant #01	—	R 519	—	17.6 mo	33.7 mo	—	—	8
ADT and Abiraterone Variant #01	—	R 369	—	—	76.6 mo	—	—	3
ADT and Flutamide Variant #01	—	R 37	—	—	—	—	—	1
ADT and Bicalutamide Variant #01	—	R 17	—	5.8 mo	—	—	—	4
ADT and Nilutamide Variant #01 Partial	—	—	—	—	—	—	—	1
Intermittent ADT Variant #01 Partial	—	—	240d	—	83.4 mo	—	—	3
Nilutamide and Orchiectomy Variant #01 Partial	—	—	30d	—	—	—	—	—
Histrelin monotherapy Variant #01 Partial	—	—	—	—	—	—	—	—
Abarelix monotherapy Variant #01 Partial	—	—	30d	—	—	—	—	—
Relugolix monotherapy Variant #01 Partial	—	—	336d	—	—	—	—	—
ADT Variant #01 Partial	—	—	—	—	52.0 mo	—	—	14

26 of 26 regimens shown